Clinical Trial to Evaluate Efficacy and Safety of SID142 in Patients With Chronic Artery Occlusive Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

170 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-02-20

Study Completion Date

2018-10-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Rinexin® Tab (Cilostazol 100mg, Ginkgo biloba leaf extract 80mg) has been widely used as an anti-platelet agent for the treatment of PAD. SID142 is a new controlled-release product improved patient's convenience and disadvantage of dosage regimen of previous drug. The aim of this study was to compare the efficacy and safety of SID142 and Rinexin® Tab in patients with PAD

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Trial to Evaluate Efficacy and Safety of DP-R202 and Anplag in Patients With Artery Occlusive Disease

NCT02393612

Peripheral Arterial Disease

COMPLETED PHASE3

Efficacy Study of Oral L-Citrulline in Patients Taking Simvastatin With Peripheral Arterial Disease

NCT00351286

Peripheral Arterial Disease Intermittent Claudication

UNKNOWN PHASE2

A Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC)

NCT05618691

Intermittent Claudication Peripheral Artery Disease

WITHDRAWN PHASE2

Efficacy and Safety of Diosmin 600mg Versus Placebo on Painful Symptomatology in Patients With Chronic Venous Disease of Lower Limbs

NCT01532882

Chronic Venous Disease of Lower Limbs

COMPLETED PHASE3

Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease

NCT00443287

Intermittent Claudication

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This clinical trial is 12 weeks, multicenter, randomized, double-blind, parallel group, phase 3 study which registered patients in total 19 institutions appointed as national clinical trial institution, it was conducted by receiving IRB(institutional review board) approval from each institutions.

Target patients were aged over 20 years old male or female lower limb peripheral artery occlusion patients with fontaine stage II/III, who has lower limb pain. Lower limb pain degree is over 40 mm evaluated by VAS at screening, and ABI (ankle-brachial index) ≤0.9 or stenosis rate over \>50%, diagnosed with PAD and voluntarily agreed to participate in clinical study and signed study consent form. Study subjects who met subjects criteria and recruited were total 170 subjects. Selected subjects were stratified by 1:1 ratio and randomly assigned to investigational product or comparator.

Investigational product was SID142 and comparator was Rinexin® Tab (Cilostazol 100mg, Ginkgo biloba leaf extract 80mg). Administration period to subjects was 12 weeks, study group took investigational product, SID1421 tab once(morning) and took placebo 1 tab/once, 2 times/day, and comparator group took investigational product, Rinexin® Tab 1 tab/once, 2 times/day and took placebo 1 tab once(morning).

Efficacy and Safety Assessment Parameter Subjects visited at 4, 8, and 12 weeks including baseline visit (visit 2) at 4 weeks interval and took efficacy and safety.

Variation in lower limb pain (VAS) comparing baseline with 12 weeks point as a primary efficacy Assessment parameter, variation in lower limb pain (VAS) comparing baseline with 4, 8 weeks, ankle brachial pressure index (ABI), ankle systolic pressure (ASP), Maximum Walking Distance (MWD), Pain Free Walking Distance (PFWD), andInvestigator's global assessment (5-point scale) as secondary efficacy assessment parameters, efficacy was measured. Pain and coldness test was measured using pain and coldness felt by subject 24 hours prior to the visit, MWD and PFWD was measured only on subjects who was determined to be possible to measure. Also, adverse event, laboratory test, vital sign, were conducted for safety assessment. Physical test and vital sign were conducted at screening visit, administration begins, 4, 8, and 12 weeks and urine pregnancy test and laboratory test were conducted at screening visits and 12 weeks. ECG test was conducted at screening visit, 4, 8, and 12 weeks after. Laboratory test criteria were hematological test, blood chemical test, blood coagulation test and urine test.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Arterial Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SID142

Patients administrate SID142 (Cilostazol 200mg, Ginkgo biloba leaf extract 160mg) once a day for 12 weeks

Group Type EXPERIMENTAL

SID142

Intervention Type DRUG

SID142 is administrated to patients with PAD for 12 weeks

Rinexin® Tab

Patients administrate Rinexin® Tab (Cilostazol 100mg, Ginkgo biloba leaf extract 80mg) twice a day for 12 weeks

Group Type ACTIVE_COMPARATOR

Rinexin® Tab

Intervention Type DRUG

Rinexin® Tab is administrated to patients with PAD for 12 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SID142

SID142 is administrated to patients with PAD for 12 weeks

Intervention Type DRUG

Rinexin® Tab

Rinexin® Tab is administrated to patients with PAD for 12 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Placebo (For Rinexin® Tab) Placebo (For SID142)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or Female outpatients over 20years of age
2. patients confirmed to have PAD

* ABI ≤0.9
* Occlusion rate\>50%
3. LE PAD with Fontaine stage II/III
4. LE pain VAS≥40mm at screening

Exclusion Criteria

1. Patients who underwent vascular surgery or endovascular procedure for PAD within 1month prior to study. Patients who need vascular surgery or endovascular procedure for PAD during this study also should be excluded.
2. Patients with peripheral neuropathy.
3. Patients with ischemic heart diseases or underwent percutaneous transluminal coronary angioplasty or coronary artery bypass graft within 6 months prior to study.
4. Patients who has diagnosed cerebrovascular diseases within 6 months prior to study.
5. Patients with hemorrhage or predisposition to hemorrhage at screening visit.
6. Uncontrolled hypertension defined as ≥ 180 mmHg of systolic blood pressure or ≥ 110 mmHg of diastolic blood pressure

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No